EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Early COVID‐19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023–January 2024

Liliana Antunes iD, Clara Mazagatos iD, Iván Martínez-Baz iD, Reinout Naesens iD, Maria-Louise Borg, Goranka Petrović iD, Terra Fatukasi iD, Ligita Jancoriene iD, Ausenda Machado iD, Beatrix Oroszi iD, Petr Husa iD, Mihaela Lazar iD und 18 weitere

Influenza and Other Respiratory Viruses · 2024

DOI: 10.1111/irv.13360 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Influenza and Other Respiratory Viruses, 2024. Verfasst von Liliana Antunes und 29 weiteren Autor:innen. Beteiligte Einrichtung: Epidemiology Department, Epiconcept, Paris, France. Hauptthemen laut MEDLINE: Hospitalization, COVID-19, COVID-19 Vaccines, SARS-CoV-2. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Centre for Disease Prevention and Control.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We conducted a multicentre test‐negative case–control study covering the period from October 2023 to January 2024 among adult patients aged ≥ 18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID‐19 vaccines against PCR‐confirmed SARS‐CoV‐2 hospitalisation. Vaccine effectiveness was 49% overall, ranging between 69% at 14–29 days and 40% at 60–105 days post vaccination. The adapted XBB.1.5 COVID‐19 vaccines conferred protection against COVID‐19 hospitalisation in the first 3.5 months post vaccination, with VE > 70% in older adults (≥ 65 years) up to 1 month post vaccination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HospitalizationCOVID-19COVID-19 VaccinesSARS-CoV-2Vaccine EfficacyVaccinationHumansAgedEuropeFemaleMaleMiddle AgedAdultCase-Control StudiesYoung AdultAged, 80 and overAdolescent

Stichwörter der Autor:innen

COVID‐19 XBB.1.5 vaccineEuropeSARS‐CoV‐2 hospitalisationvaccine effectiveness

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Epidemiology Department, Epiconcept, Paris, France.
  • National Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain.
  • Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain.
  • Department of Medical Microbiology and Infection Prevention & Control, Ziekenhuisnetwerk Antwerpen, Antwerp, Belgium.
  • Infectious Disease Prevention and Control Unit (IDCU), Health Promotion and Disease Prevention, Msida, Malta.

ORCID-Profile: Liliana Antunes, Clara Mazagatos, Iván Martínez-Baz, Reinout Naesens, Goranka Petrović, Terra Fatukasi, Ligita Jancoriene, Ausenda Machado, Beatrix Oroszi, Petr Husa, Mihaela Lazar, Ralf Dürrwald, Jennifer Howard, Aryse Melo, Gloria Pérez-Gimeno, Jesús Castilla, Aušra Džiugytė, Zvjezdana Lovrić Makarić, Margaret Fitzgerald, Verónica Gomez, Gergő Túri, Lenka Součková, Alexandru Marin, Kristin Tolksdorf, Nathalie Nicolay, Angela M C Rose

Förderung

  • European Centre for Disease Prevention and Control

Zitieren

APA

Antunes, L., Mazagatos, C., Martínez-Baz, I., Naesens, R., Borg, M. L., Petrović, G., Fatukasi, T., Jancoriene, L., Machado, A., Oroszi, B., Husa, P., Lazar, M., Dürrwald, R., Howard, J., Melo, A., Pérez-Gimeno, G., Castilla, J., Bernaert, E., Džiugytė, A., …, & European Hospital Vaccine Effectiveness Group (2024). Early COVID‐19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023–January 2024. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.13360

Vancouver

Antunes L, Mazagatos C, Martínez-Baz I, Naesens R, Borg ML, Petrović G, et al. Early COVID‐19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023–January 2024. Influenza and Other Respiratory Viruses. 2024. doi:10.1111/irv.13360

BibTeX
@article{Antunes2024,
  author = {Antunes, Liliana and Mazagatos, Clara and Martínez-Baz, Iván and Naesens, Reinout and Borg, Maria-Louise and Petrović, Goranka and Fatukasi, Terra and Jancoriene, Ligita and Machado, Ausenda and Oroszi, Beatrix and Husa, Petr and Lazar, Mihaela and Dürrwald, Ralf and Howard, Jennifer and Melo, Aryse and Pérez-Gimeno, Gloria and Castilla, Jesús and Bernaert, Eva and Džiugytė, Aušra and Makarić, Zvjezdana Lovrić and Fitzgerald, Margaret and Mickienė, Auksė and Gomez, Verónica and Túri, Gergő and Součková, Lenka and Marin, Alexandru and Tolksdorf, Kristin and Nicolay, Nathalie and Rose, Angela M C and European Hospital Vaccine Effectiveness Group, European Hospital Vaccine Effectiveness Group},
  title = {Early COVID‐19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023–January 2024},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2024},
  doi = {10.1111/irv.13360}
}
Kostenlos starten →